6Suppliers
2Customers
3Debt Items
20Related Chains

Quince Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
CANTOR-FITZGERALD-CO CANTOR-FITZGERALD-CO 90% On December 18, 2024, we entered into a Controlled Equity Offering Sales Agreement, with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC, or the Agents, relating to the sale of shares of our c…
EUROPEAN-INVESTMENT-BANK EUROPEAN-INVESTMENT-BANK 90% As a result of the Company’s payment of such amount, the Company’s and the Borrower’s obligations under the finance documents were deemed satisfied.
H-C-WAINWRIGHT-CO-LLC H-C-WAINWRIGHT-CO-LLC 90% On December 18, 2024, we entered into a Controlled Equity Offering Sales Agreement, with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC, or the Agents, relating to the sale of shares of our c…
PRF PRF 80% Under the Termination Agreement, we agreed to reimburse PRF for certain fees and costs incurred in connection with the prosecution of the licensed patents prior to termination
ORANY ORANY 72% nications containing warning or other safety information about the product; • fines, warning letters or holds on post-approval clinical trials; • refusal of the FDA to approve pending NDAs or supplem…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from QNCX graph: nications containing warning or other safety information about the product; • fines, warning letters or holds on pos…

Quince Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
ORANY ORANY 72% nications containing warning or other safety information about the product; • fines, warning letters or holds on post-approval clinical trials; • refusal of the FDA to approve pending NDAs or supplem…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from QNCX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from QNCX graph: Reciprocal relationship from ORAN…

Quince Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
QNCX-DEBT Debt stack $293,000 90% Market cache reports total debt of $293,000.
QNCX-DEBT-11996 Warrants outstanding: 27941 90% xbrl warrant detail from xbrl 2025-12-31.
QNCX-DEBT-11997 Xbrl Convertible 90% xbrl convertible detail from xbrl 2019-12-31.

Quince Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
QNCX-OWNER-NANTAHALA-CAPITAL-MANAGEMENT-LLC Nantahala Capital Management, LLC 95% 13F/ownership overlay lists Nantahala Capital Management, LLC; shares held 2,672,429; ownership 2.53%; value $435,605; as of 2025-12-31.
QNCX-OWNER-IEQ-CAPITAL-LLC IEQ Capital, LLC 95% 13F/ownership overlay lists IEQ Capital, LLC; shares held 979,275; ownership 0.93%; value $159,621; as of 2025-12-31.
QNCX-OWNER-VANGUARD-GROUP-INC Vanguard Group Inc 95% 13F/ownership overlay lists Vanguard Group Inc; shares held 2,084,015; ownership 1.97%; value $339,694; as of 2025-12-31.
QNCX-OWNER-ALMITAS-CAPITAL-LLC Almitas Capital LLC 95% 13F/ownership overlay lists Almitas Capital LLC; shares held 930,134; ownership 0.88%; value $151,611; as of 2025-12-31.
QNCX-OWNER-MILLENNIUM-MANAGEMENT-LLC Millennium Management Llc 95% 13F/ownership overlay lists Millennium Management Llc; shares held 1,190,352; ownership 1.13%; value $194,027; as of 2025-12-31.
QNCX-OWNER-WOODLINE-PARTNERS-LP Woodline Partners LP 95% 13F/ownership overlay lists Woodline Partners LP; shares held 1,941,542; ownership 1.84%; value $316,471; as of 2025-12-31.
QNCX-OWNER-SUPERSTRING-CAPITAL-MANAGEMENT-LP Superstring Capital Management LP 95% 13F/ownership overlay lists Superstring Capital Management LP ; shares held 858,711; ownership 0.81%; value $139,969; as of 2025-12-31.
QNCX-OWNER-STEMPOINT-CAPITAL-LP Stempoint Capital LP 95% 13F/ownership overlay lists Stempoint Capital LP ; shares held 739,264; ownership 0.70%; value $120,500; as of 2025-12-31.
QNCX-OWNER-RENAISSANCE-TECHNOLOGIES-LLC Renaissance Technologies, LLC 95% 13F/ownership overlay lists Renaissance Technologies, LLC; shares held 538,100; ownership 0.51%; value $87,710; as of 2025-12-31.
QNCX-OWNER-ADAGE-CAPITAL-PARTNERS-GP-L-L-C Adage Capital Partners GP L.L.C. 95% 13F/ownership overlay lists Adage Capital Partners GP L.L.C.; shares held 2,250,000; ownership 2.13%; value $366,750; as of 2025-12-31.

Quince Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ORANY ORANGE 100.00 1 ['customer', 'supplier']
AMZE Amaze Holdings, Inc. 50.00 2
DWTX Dogwood Therapeutics, Inc. 50.00 2
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
CHUC Charlie's Holdings, Inc. 50.00 2
CLNE Clean Energy Fuels Corp. 50.00 2
FENC Fennec Pharmaceuticals Inc. 50.00 2
EQR Equity Residential 50.00 2
CNOB ConnectOne Bancorp, Inc. 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
ESS Essex Property Trust, Inc. 50.00 2
ED Consolidated Edison, Inc. 50.00 2
SCNX Scienture Holdings, Inc. 50.00 2
CORT Corcept Therapeutics Incorporated 50.00 2
BLTE Belite Bio, Inc 50.00 2